This is a pregnancy outcomes study in women exposed to BREXAFEMME® (ibrexafungerp tablets) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving last dose of the treatment. BREXAFEMME® is contraindicated during pregnancy because animal studies have indicated that it may cause fetal harm.
The purpose of this study is to monitor and document the pregnancy outcomes of women who have taken BREXAFEMME® during pregnancy. The study will observe patients throughout pregnancy and will monitor their infants from birth to the age of 12 months.
Call the toll-free number 1‑888‑982‑7299 and speak to a study representative.
You may participate in this study: